NAA50 and neuroblastoma: Based on these results, we designed an assay strategy to gate neuroblastoma cells from a mixed population of cells in clinical samples by identifying neuroblastoma cells using positive HSAN staining and then quantifying GD2 surface levels using dinutuximab Alexa Fluor 647 (Figure 2).